Venus Medtech (Hangzhou) Inc.
VMTHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $470,833 | $491,373 | $406,461 | $415,862 |
| % Growth | -4.2% | 20.9% | -2.3% | – |
| Cost of Goods Sold | $103,087 | $102,168 | $92,463 | $91,518 |
| Gross Profit | $367,746 | $389,205 | $313,998 | $324,344 |
| % Margin | 78.1% | 79.2% | 77.3% | 78% |
| R&D Expenses | $341,185 | $524,915 | $527,451 | $258,336 |
| G&A Expenses | $146,026 | $153,786 | $192,178 | $128,585 |
| SG&A Expenses | $391,092 | $454,263 | $452,560 | $344,652 |
| Sales & Mktg Exp. | $245,066 | $300,477 | $260,382 | $216,067 |
| Other Operating Expenses | -$17,934 | -$1,428 | -$31,128 | -$6,687 |
| Operating Expenses | $714,343 | $977,750 | $948,883 | $596,301 |
| Operating Income | -$346,597 | -$589,973 | -$650,214 | -$278,644 |
| % Margin | -73.6% | -120.1% | -160% | -67% |
| Other Income/Exp. Net | -$394,116 | -$146,795 | -$506,130 | -$98,911 |
| Pre-Tax Income | -$740,713 | -$735,340 | -$1,156,344 | -$377,555 |
| Tax Expense | -$23,340 | -$6,284 | -$34,302 | -$6,161 |
| Net Income | -$714,307 | -$703,754 | -$1,057,699 | -$373,636 |
| % Margin | -151.7% | -143.2% | -260.2% | -89.8% |
| EPS | -1.63 | -1.61 | -2.42 | -0.85 |
| % Growth | -1.2% | 33.5% | -184.7% | – |
| EPS Diluted | -1.63 | -1.61 | -2.42 | -0.85 |
| Weighted Avg Shares Out | 437,897 | 437,897 | 437,898 | 438,577 |
| Weighted Avg Shares Out Dil | 437,897 | 437,897 | 437,897 | 438,577 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10,350 | $34,457 | $34,648 | $49,480 |
| Interest Expense | $16,647 | $62,716 | $44,623 | $1,905 |
| Depreciation & Amortization | $111,109 | $124,787 | $112,352 | $51,621 |
| EBITDA | -$612,957 | -$547,837 | -$999,369 | -$324,029 |
| % Margin | -130.2% | -111.5% | -245.9% | -77.9% |